Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2032

Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.

Patents
1,150

Quick answer

1,150 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8299040

    Methods for treating cancer targeting transglutaminase

    The Board of Regents of the University of Texas System · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8299033

    Iodo-hexose compounds useful to treat cancer

    The Board of Regents of the University of Texas System · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8298589

    Nitrite formulations and their use as nitric oxide prodrugs

    The Board of Regents of the University of Texas System · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8298580

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8298556

    Methods and related compositions for the non-surgical removal of fat

    The Regents of the University of California · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8298521

    Treatment for eye disorder

    The Regents of the University of California · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8298523

    Compositions containing interleukin-1 and peptides

    United Technologies UT AG · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8298532

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8298541

    Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8298542

    Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia

    The Board of Regents of the University of Texas System · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8298546

    Isolation and purification of P. falciparum merozoite protein-142 vaccine

    The United States of America as represented by the Secretary of the Army · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8298555

    Color cosmetic compositions for topical anti-aging skin treatment

    Discovery Limited · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8298576

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8299099

    Heteroaryl derivatives as CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8299101

    1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators

    Addex Pharma, S.A. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8299173

    Method involving 1-benzotriazolyl carbonate esters of polymers

    Nektar Therapeutics · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8299218

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8304399

    Hedgehog signaling pathway proteins and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8304397

    Identification of a micro-RNA that activates expression of β-myosin heavy chain

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8304247

    Recognitive hydrogel

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8304439

    Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage

    POLITECHNIKA LÓDZKA · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8304432

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8304433

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8304422

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8304511

    Maleamic acid polymer derivatives and their bioconjugates

    Nektar Therapeutics · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8304414

    Pyrazole compounds useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8304383

    Dissolution of arterial plaque

    Atheronova Operations, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8304557

    Fused heterocycle derivatives and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8304526

    Antitumor effect of mutant Bik

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8303985

    Skin treatment compositions containing copper-pigment complexes

    Discovery Limited · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8304577

    Modulators of G protein-coupled receptor 88

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8304428

    Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

    Infinity Discovery, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8304423

    Modulators of muscarinic receptors

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8303984

    Skin treatment compositions containing copper-pigment complexes

    Discovery Limited · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8303960

    Radiolabeled affibody molecules

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8304408

    Wnt signaling inhibitors, and methods for making and using them

    The Regents of the University of California · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8303995

    Nitrite formulations and their use as nitric oxide prodrugs

    The Board of Regents of the University of Texas System · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8304385

    Macrocyclic tetrazolyl hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8309071

    Foamy viral envelope genes

    Vectoria Forschungsforderungs Verein E.V. · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8309701

    Variants of human taste receptor genes

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8309766

    Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8309566

    Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

    Rigel Pharmaceuticals, Inc. · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8309543

    Compositions useful as inhibitors of voltage-gated sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8309355

    Methods of treating Parkinson's disease using viral vectors

    The Regents of the University of California · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8309680

    Segmented degradable polymers and conjugates made therefrom

    Nektar Therapeutics · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8309595

    Hydrazone modulators of cannabinoid receptors

    The Board of Regents of the University of Texas System · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8309587

    Piperidine and piperazine phenyl sulphonamides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8309580

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2032?

1,150 published patents in our USPTO index have expiration dates falling in calendar year 2032.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.